Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: Costs of reperfusion strategies in acute myocardial infarction

American Heart Journal

Volumn 149, Issue 4, 2005, Pages 637-644

  Kaul, Padma ^a,b   Armstrong, Paul W ^b   Cowper, Patricia A ^a   Eisenstein, Eric L ^a   Granger, Christopher B ^a   Van De Werf, Frans ^c   Mark, Daniel B ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ENOXAPARIN; HEPARIN; TENECTEPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEART MUSCLE REPERFUSION; HOSPITAL BILLING; HOSPITAL CHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; REIMBURSEMENT; RISK ASSESSMENT; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UNITED STATES;

EID: 17044413615     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.02.019     Document Type: Article

References (14)

1. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) Investigators Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction Lancet 358 2001 605 613
2. L. Wallentin, B. Lindahl, and P.W. Armstrong Influence of enoxaparin and early revascularization on death or myocardial infarction after thrombolysis in ST elevation myocardial infarction Eur. Heart J. 23 Suppl. 2002 639
3. E.M. Antman, H.W. Louwerenburg, and H.F. Baars Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial Circulation 105 2002 1642 1649
4. Centers for Medicare and Medicaid Services Medicare Provider Analysis and Review (MEDPAR) 2001 http://cms.hhs.gov/statistics/medpar/default.asp
5. C. Kirschner, J. Kopacz, and D. Reyes Current procedural terminology: CPT 2001 4th ed. 2001 American Medical Association Chicago (Ill)
6. The GUSTO-2b Investigators A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes N. Engl. J. Med. 335 1996 775 782
7. E.L. Eisenstein, L.K. Shaw, and K.J. Anstrom Assessing the clinical and economic burden of coronary artery disease: 1986-1998 Med. Care 39 2001 824 835
8. 2001 Drug topics red book 2001 Medical Economics Data Montvale (NJ)
9. D.B. Mark, P.A. Cowper, and S.D. Berkowitz Economic assessment of low-molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial Circulation 97 1998 1702 1707
10. D.B. Mark, and M.A. Hlatky Medical economics and the assessment of value in cardiovascular medicine: Part I Circulation 106 2002 516 520
11. J.C. Wright, and M.C. Weinstein Gains in life expectancy from medical interventions-standardizing data on outcomes N. Engl. J. Med. 339 1998 380 386
12. D.B. Mark, R.A. Harrington, and A.M. Lincoff Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST elevation acute coronary syndromes Circulation 101 2000 366 371
13. M.P. Hudson, C.B. Granger, and E.J. Topol Early reinfarction after fibrinolysis: experience from the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO-I) and Global use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) trials Circulation 104 2001 1229 1235
14. D.B. Mark, M.A. Hlatky, and R.M. Califf Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction N. Engl. J. Med. 332 1995 1418 1424